What is the acyclovir injection used for?
Pharmaceutical Product Monograph: Acyclovir Injection (500 mg)
In the pharmaceutical industry, Acyclovir is a synthetic purine nucleoside analogue. As a pharmacist and manufacturer, I view this molecule as a “Selective DNA Polymerase Inhibitor”—it is technically designed to remain inactive in healthy cells and only become “armed” inside cells already infected by specific herpes viruses.
At your WHO-GMP facility in Mumbai, Acyclovir injection is a critical antiviral SKU, primarily used for severe, systemic, or life-threatening viral infections where oral tablets would be insufficiently absorbed or too slow to act.
Therapeutic Profile: Primary Indications
Acyclovir injection is reserved for serious viral conditions requiring high plasma concentrations.
| Indication | Clinical Context | Technical Rationale |
| Herpes Encephalitis | Brain Infection | First-line treatment. High-dose IV therapy is mandatory to cross the blood-brain barrier and prevent permanent neurological damage. |
| Neonatal Herpes | Newborn Infection | Critical for infants born to mothers with active herpes to prevent disseminated organ failure. |
| Immunocompromised Patients | Opportunistic Infection | Used in HIV/AIDS or transplant patients to treat severe mucocutaneous or visceral herpes outbreaks. |
| Severe Genital Herpes | Initial Outbreak | For patients with extensive lesions or systemic symptoms (fever, malaise) that prevent oral intake. |
| Varicella-Zoster (Shingles) | Disseminated Disease | Used when shingles spreads to multiple dermatomes or affects the internal organs (visceral zoster). |
Mechanism: Selective Phosphorylation & Chain Termination
Acyclovir’s “smart” mechanism ensures it targets the virus while sparing the host cell:
Viral Activation: Acyclovir is a “prodrug.” It must be converted into its active form by the viral enzyme Thymidine Kinase (TK). Because human cells do not have this specific enzyme, the drug remains largely inactive in healthy cells.
Conversion to Triphosphate: Once the virus “activates” the drug, cellular enzymes further convert it into Acyclovir Triphosphate.
DNA Polymerase Inhibition: The active drug competes with natural deoxyguanosine triphosphate to be included in the viral DNA chain.
Chain Termination: Technically, Acyclovir lacks the “chemical hook” (the 3′-hydroxyl group) needed to attach the next building block of DNA. Once it is inserted, the viral DNA chain breaks, and replication stops instantly.
The Pharmacist’s “Technical Warning”
The “Slow Infusion” Rule: As a pharmacist, I must emphasize that Acyclovir must be infused over at least 1 hour. Rapid “bolus” injection can cause the drug to precipitate into crystals in the kidneys, leading to acute renal failure.
Hydration is Mandatory: Patients must be well-hydrated before and during the infusion to “flush” the drug through the renal tubules.
Neurological Side Effects: High doses can technically cause tremors, confusion, or even seizures, especially in elderly patients or those with pre-existing kidney disease.
Phlebitis: The solution is highly alkaline (pH ~11). It must be diluted properly to prevent severe vein irritation (phlebitis) at the injection site.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Lyophilization” USP: On your digital marketplace, highlight your Lyophilized (Freeze-Dried) Powder technology. Acyclovir is more stable as a dry powder, ensuring a 36-month shelf life in the high-heat Zone IVb export markets compared to liquid versions.
Ideal Body Weight Dosing: For your B2B clinical dossiers, note that for obese patients, dosing should technically be based on Ideal Body Weight (IBW) rather than total body weight to prevent overdosage.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Acyclovir 500 mg vials to support your registration in international tenders for infectious disease and pediatric care.